FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children
The FDA has expanded the approval for Merck's Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Tag: Pneumococcus
All
Latest
All
Latest
Investigating the Role of Nasal Flora and Viral Infection on Acquisition of Pneumococcus
Identification of specific microbiota constellations which appear to control viral and bacterial acquisition might help develop new therapeutic strategies for respiratory infections.